Incorporation of ABCB1-mediated transport into a physiologically-based pharmacokinetic model of docetaxel in mice

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 40, Issue 4, 2013, Pages 437-449

  Hudachek, Susan F ^a   Gustafson, Daniel L ^a  

^a Department of Ecosystem Science and Sustainability   (United States)

Author keywords

ABCB1; Docetaxel; MDR1; PGP; Physiologically based pharmacokinetic modeling

Indexed keywords

DOCETAXEL; MULTIDRUG RESISTANCE PROTEIN 1; TUBULIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; FEMALE; GLOMERULUS FILTRATION; INTESTINE METABOLISM; KIDNEY TUBULE ABSORPTION; LIVER METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; SINGLE DRUG DOSE; TISSUE DISTRIBUTION; TISSUE METABOLISM;

ADMINISTRATION, INTRAVENOUS; ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; FEMALE; GLOMERULAR FILTRATION RATE; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; TAXOIDS; TISSUE DISTRIBUTION; TUBULIN;

EID: 84881176239     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-013-9317-1     Document Type: Article

References (54)

1. Bruno R, Vivier N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB (1996) A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm 24(2):153-172
2. Bruno R, Sanderink GJ (1993) Pharmacokinetics and metabolism of Taxotere (docetaxel). Cancer Surv 17:305-313
3. Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M, Rahmani R (1996) Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 56(6):1296-1302
4. Shirakawa K, Takara K, Tanigawara Y, Aoyama N, Kasuga M, Komada F, Sakaeda T, Okumura K (1999) Interaction of docetaxel (Taxotere) with human P-glycoprotein. Jpn J Cancer Res 90(12):1380-1386
5. Gros P, Croop J, Housman D (1986) Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 47(3):371-380
6. Hsu SI, Lothstein L, Horwitz SB (1989) Differential overexpression of three mdr gene family members in multidrug-resistant J774.2 mouse cells. Evidence that distinct P-glycoprotein precursors are encoded by unique mdr genes. J Biol Chem 264(20):12053-12062
7. Devault A, Gros P (1990) Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Mol Cell Biol 10(4):1652-1663
8. Croop JM, Raymond M, Haber D, Devault A, Arceci RJ, Gros P, Housman DE (1989) The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol 9(3):1346-1350
9. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84(21):7735-7738
10. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86(2):695-698
11. Sugawara I, Kataoka I, Morishita Y, Hamada H, Tsuruo T, Itoyama S, Mori S (1988) Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res 48(7):1926-1929
12. Dano K (1973) Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Acta 323(3):466-483
13. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5(3):219-234
14. Krishnan K, Loizou GD, Spendiff M, Lipscomb JC, Andersen ME (2010) PBPK modeling: a primer. In: Krishnan K, Andersen ME (eds) Quantitative modeling in toxicology. Wiley, Chichester, p xvii, 485
15. Andersen ME, Yang RSH, Clewell HJ 3rd, Reddy MB (2005) Introduction: a historical perspective of the development and applications of PBPK models. In: Reddy MB, Yang RSH, Clewell HJ 3rd, Andersen ME (eds) Physiologically based pharmacokinetic modeling: science and applications. Wiley-Interscience, Hoboken, p xix, 420
16. Norris DA, Leesman GD, Sinko PJ, Grass GM (2000) Development of predictive pharmacokinetic simulation models for drug discovery. J Control Release 65(1-2):55-62
17. Theil FP, Guentert TW, Haddad S, Poulin P (2003) Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicol Lett 138(1-2):29-49
18. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van der Valk MA, Voordouw AC, Spits H, van Tellingen O, Zijlmans JM, Fibbe WE, Borst P (1997) Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 94(8):4028-4033
19. Bradshaw-Pierce EL, Eckhardt SG, Gustafson DL (2007) A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man. Clin Cancer Res 13(9):2768-2776
20. Gustafson DL, Long ME, Zirrolli JA, Duncan MW, Holden SN, Pierson AS, Eckhardt SG (2003) Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay. Cancer Chemother Pharmacol 52(2):159-166
21. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP (1997) Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13(4):407-484
22. Urien S, Barre J, Morin C, Paccaly A, Montay G, Tillement JP (1996) Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein. Investig New Drugs 14(2):147-151
23. Wierzba K, Sugiyama Y, Okudaira K, Iga T, Hanano M (1987) Tubulin as a major determinant of tissue distribution of vincristine. J Pharm Sci 76(12):872-875
24. Diaz JF, Andreu JM (1993) Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 32(11):2747-2755
25. Chabner B, Longo DL (2010) Cancer chemotherapy and biotherapy: principles and practice, 5th edn. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia
26. Huls M, Kramers C, Levtchenko EN, Wilmer MJ, Dijkman HB, Kluijtmans LA, van der Hoorn JW, Russel FG, Masereeuw R (2007) P-glycoprotein-deficient mice have proximal tubule dysfunction but are protected against ischemic renal injury. Kidney Int 72(10):1233-1241
27. van Herwaarden AE, Wagenaar E, van der Kruijssen CM, van Waterschoot RA, Smit JW, Song JY, van der Valk MA, van Tellingen O, van der Hoorn JW, Rosing H, Beijnen JH, Schinkel AH (2007) Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Investig 117(11):3583-3592
28. Zhang QY, Dunbar D, Kaminsky LS (2003) Characterization of mouse small intestinal cytochrome P450 expression. Drug Metab Dispos 31(11):1346-1351
29. Loccisano AE, Campbell JL Jr, Butenhoff JL, Andersen ME, Clewell HJ 3rd (2012) Comparison and evaluation of pharmacokinetics of PFOA and PFOS in the adult rat using a physiologically based pharmacokinetic model. Reprod Toxicol 33(4):452-467
30. Hudachek SF, Gustafson DL (2013) Physiologically based pharmacokinetic model of lapatinib developed in mice and scaled to humans. J Pharmacokinet Pharmacodyn 40(2):157-176
31. van Waterschoot RA, Schinkel AH (2011) A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: recent insights from knockout and transgenic mice. Pharmacol Rev 63(2):390-410
32. Benet LZ (2009) The drug transporter-metabolism alliance: uncovering and defining the interplay. Mol Pharm 6(6):1631-1643
33. Bardelmeijer HA, Ouwehand M, Buckle T, Huisman MT, Schellens JH, Beijnen JH, van Tellingen O (2002) Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res 62(21):6158-6164
34. Bischoff KB, Dedrick RL, Zaharko DS (1970) Preliminary model for methotrexate pharmacokinetics. J Pharm Sci 59(2):149-154
35. Bischoff KB, Dedrick RL, Zaharko DS, Longstreth JA (1971) Methotrexate pharmacokinetics. J Pharm Sci 60(8):1128-1133
36. Zaharko DS, Dedrick RL, Bischoff KB, Longstreth JA, Oliverio VT (1971) Methotrexate tissue distribution: prediction by a mathematical model. J Natl Cancer Inst 46(4):775-784
37. Evans WE, Crom WR, Tsiatis A, Green AA, Hayes FA, Pratt CB (1982) Pharmacokinetic modeling of cisplatin disposition in children and adolescents with cancer. Cancer Chemother Pharmacol 10(1):22-26
38. Lutz RJ, Galbraith WM, Dedrick RL, Shrager R, Mellett LB (1977) A model for the kinetics of distribution of actinomycin-D in the beagle dog. J Pharmacol Exp Ther 200(3):469-478
39. Collins JM, Dedrick RL, King FG, Speyer JL, Myers CE (1980) Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes. Clin Pharmacol Ther 28(2):235-246
40. Tsukamoto Y, Kato Y, Ura M, Horii I, Ishitsuka H, Kusuhara H, Sugiyama Y (2001) A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU. Pharm Res 18(8):1190-1202
41. Dedrick RL, Forrester DD, Ho DH (1972) In vitro-in vivo correlation of drug metabolism-deamination of 1-D-arabinofuranosylcytosine. Biochem Pharmacol 21(1):1-16
42. Harris PA, Gross JF (1975) Preliminary pharmacokinetic model for adriamycin (NSC-123127). Cancer Chemother Rep 59(4):819-825
43. Chan KK, Cohen JL, Gross JF, Himmelstein KJ, Bateman JR, Tsu-Lee Y, Marlis AS (1978) Prediction of adriamycin disposition in cancer patients using a physiologic, pharmacokinetic model. Cancer Treat Rep 62(8):1161-1171
44. Gustafson DL, Rastatter JC, Colombo T, Long ME (2002) Doxorubicin pharmacokinetics: macromolecule binding, metabolism, and excretion in the context of a physiologic model. J Pharm Sci 91(6):1488-1501
45. Sung C, Blaney SM, Cole DE, Balis FM, Dedrick RL (1994) A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid. Cancer Res 54(19):5118-5122
46. Kemper EM, Verheij M, Boogerd W, Beijnen JH, van Tellingen O (2004) Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein. Eur J Cancer 40(8):1269-1274
47. Padowski JM, Pollack GM (2010) Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Methods Mol Biol 596:359-384
48. Badhan R, Penny J, Galetin A, Houston JB (2009) Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption. J Pharm Sci 98(6):2180-2197
49. Kivisto KT, Niemi M, Fromm MF (2004) Functional interaction of intestinal CYP3A4 and P-glycoprotein. Fundam Clin Pharmacol 18(6):621-626
50. Fenneteau F, Turgeon J, Couture L, Michaud V, Li J, Nekka F (2009) Assessing drug distribution in tissues expressing P-glycoprotein through physiologically based pharmacokinetic modeling: model structure and parameters determination. Theor Biol Med Model 6:2
51. Robey RW, Massey PR, Amiri-Kordestani L (2010) Bates SE ABC transporters: unvalidated therapeutic targets in cancer and the CNS. Anticancer Agents Med Chem 10(8):625-633
52. Fung KL, Gottesman MM (2009) A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta 1794(5):860-871
53. Bosch TM, Huitema AD, Doodeman VD, Jansen R, Witteveen E, Smit WM, Jansen RL, van Herpen CM, Soesan M, Beijnen JH, Schellens JH (2006) Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin Cancer Res 12(19):5786-5793
54. Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ, Franke RM, Hu S, Schuetz EG, Lamba V, Messersmith WA, Wolff AC, Carducci MA, Sparreboom A (2009) Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther 85(2):155-163